beta Blockade after myocar- dial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 7. 419. Deleted in press. 420. Pfeffer MA, Braunwald E, Moy LA, et al; the SAVE Investigators. Ef- fect of captopril on mortality and morbidity in patients with left ventricu- lar dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669 77. 421. Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and myocardial infarction: the AIRE Study in practice: Acute Infarction Ramipril Efficacy Study. Eur Heart J. 1994;15 Suppl B:20 5; discus- sion 26 30. 422. K ber L, Torp-Pedersen C, Carlsen JE, et al; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin- converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670 6. 423. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angio- tensin-converting enzyme inhibition therapy in acute myocardial infarc- tion: the healing and early afterload reducing therapy trial. Circulation. 1997;95:2643 51. 424. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricu- lar dysfunction, or both. N Engl J Med. 2003;349:1893 906. Erratum in: N Engl J Med. 2004;350:203. 425. Maggioni AP, Fabbri G. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opin Pharmacother. 2005;6:507 12. 426. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial in- farction. N Engl J Med. 2003;348:1309 21. Erratum in: N Engl J Med. 2003;348:2271. 427. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in random- ized trials. Circulation. 1998;97:2202 12. 428. 